Cardiac Phenotypes in Fabry Disease: Genetic Variability and Clinical Severity Staging Correlation in a Reference Center Cohort
Genes · 2025
DOI: 10.3390/genes16091086 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2025. Verfasst von Denise Cristiana Faro und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery and Medical-Surgical Specialties, University of Catania, Via S. Sofia 78, 95123 Catania, Italy. Hauptthemen laut MEDLINE: Fabry Disease, alpha-Galactosidase. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Anderson–Fabry disease (AFD) presents with a wide spectrum of clinical manifestations, influenced by the underlying GLA genotype. While classical variants are typically associated with early-onset, multisystemic involvement, late-onset mutations and variants of uncertain significance (VUS) often display predominantly cardiac phenotypes. This study aimed to explore the relationship between GLA variant class, cardiovascular severity, and clinical outcomes using validated staging systems and real-world data.
Methods
In this single-centre retrospective study, we evaluated 42 patients with genetically confirmed AFD, stratified into classical, late-onset, and VUS categories. Cardiovascular involvement was assessed using three standardized staging tools—Del Franco, Meucci, and MSSI—and correlated with the occurrence and burden of major adverse cardiovascular events (MACE). Multivariable analyses were performed to adjust for age, sex, and treatment status.
Results
Classical variants were strongly associated with more advanced cardiac staging (Del Franco, Meucci) and higher MSSI scores, reflecting systemic disease severity. These patients experienced significantly more frequent and severe MACE (p = 0.022), confirming the prognostic relevance of genotypic stratification. In contrast, carriers of late-onset mutations and VUS exhibited milder phenotypes and lower event rates. Importantly, genotype remained an independent predictor of cardiovascular risk in adjusted models, suggesting a direct contribution to disease progression beyond demographic or therapeutic factors.
Conclusions
This study highlights the role of GLA genotype in shaping cardiovascular risk and clinical trajectory in AFD. Integrating genetic classification with clinical staging provides a powerful, multimodal approach to risk stratification and supports the move toward genotype-informed, personalized management strategies in AFD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery and Medical-Surgical Specialties, University of Catania, Via S. Sofia 78, 95123 Catania, Italy.
- Institute for Biomedical Research and Innovation, National Research Council (IRIB-CNR), Section of Catania, Via Paolo Gaifami 18, 95126 Catania, Italy.
- Cardiology Unit-CAST, AOU Policlinico "G. Rodolico-S. Marco", Via S. Sofia 76, 95123 Catania, Italy.
ORCID-Profile: Denise Cristiana Faro, Margherita Stefania Rodolico, Valentina Losi, Ines Paola Monte
Zitieren
APA
Faro, D. C., Di Salvo, S., Rodolico, M. S., Losi, V., Capodanno, D., & Monte, I. P. (2025). Cardiac Phenotypes in Fabry Disease: Genetic Variability and Clinical Severity Staging Correlation in a Reference Center Cohort. Genes. https://doi.org/10.3390/genes16091086
Vancouver
Faro DC, Di Salvo S, Rodolico MS, Losi V, Capodanno D, Monte IP. Cardiac Phenotypes in Fabry Disease: Genetic Variability and Clinical Severity Staging Correlation in a Reference Center Cohort. Genes. 2025. doi:10.3390/genes16091086
BibTeX
@article{Faro2025,
author = {Faro, Denise Cristiana and Di Salvo, Serena and Rodolico, Margherita Stefania and Losi, Valentina and Capodanno, Davide and Monte, Ines Paola},
title = {Cardiac Phenotypes in Fabry Disease: Genetic Variability and Clinical Severity Staging Correlation in a Reference Center Cohort},
journal = {Genes},
year = {2025},
doi = {10.3390/genes16091086}
}
EUVIMED